19 results on '"Lambrescu I"'
Search Results
2. Finite Element Stress Analysis of Pipelines with Advanced Composite Repair
- Author
-
Diniţă, A., Lambrescu, I., Chebakov, M. I., Dumitru, Gh., Barkanov, Evgeny N., editor, Dumitrescu, Andrei, editor, and Parinov, Ivan A., editor
- Published
- 2018
- Full Text
- View/download PDF
3. Finite Element Stress Analysis of Pipelines with Advanced Composite Repair
- Author
-
Diniţă, A., primary, Lambrescu, I., additional, Chebakov, M. I., additional, and Dumitru, Gh., additional
- Published
- 2017
- Full Text
- View/download PDF
4. Assessment of the Reinforcement Capacity of Composite Repair Systems for Pipelines with Interacting Defects
- Author
-
Lambrescu, I., primary, Chebanenko, V. A., additional, Gusakov, D. V., additional, and Morgunova, A. V., additional
- Published
- 2017
- Full Text
- View/download PDF
5. Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors
- Author
-
Marques, P, Caimari, F, Hernández-Ramírez, LC, Collier, D, Iacovazzo, D, Ronaldson, A, Magid, K, Lim, CT, Stals, K, Ellard, S, Grossman, AB, Korbonits, M, Abraham, P, Aflorei, E, Agha, A, Ahlquist, J, Akker, SA, Alexandraki, K, Alföldi, S, Anselmo, J, Arlt, W, Atkinson, B, Aulinas-Masó, A, Aylwin, SJ, Baborie, A, Backeljauw, PF, Badiu, C, Baldeweg, S, Ball, S, Bano, G, Barkan, A, Barton, J, Barwell, J, Bates, P, Bernal-González, C, Besser, M, Bevan, JS, Bickerton, A, Blair, J, Bolanowski, M, Bouloux, P, Bradley, L, Bradley, K, Brain, C, Brooke, A, Brown, R, Buchfelder, M, Burren, C, Cakir, M, Canham, N, Capraro, J, Carroll, P, Carter, P, Carty, D, Cavlan, D, Chahal, HS, Cheetham, T, Chentli, F, Choong, C, Christ-Crain, M, Chung, T-T, Clayton, P, Clayton, RN, Cohen, M, Courtney, H, Cove, D, Crowne, E, Cuthbertson, D, Dal, J, Dalantaeva, N, Damjanovic, S, Daousi, C, Darzy, K, Dattani, M, Davies, M, Davies, J, Davis, J, de Castro, M, de Marinis, L, Deal, C, Dénes, J, Dimitri, P, Dorward, N, Dow, G, Drake, W, Druce, M, Drummond, J, Dutta, P, Dzeranova, L, Edén-Engström, B, Eeles, R, Elfving, M, Ellis, K, Elston, M, Emmerson, L, Ezzat, S, Fersht, N, Fica, S, Fischli, S, Fleseriu, M, Forsythe, E, Foulkes, W, Freda, P, Friedman, T, Gadelha, M, Gainsborough, M, Gallacher, S, Gallego, P, Gan, H-W, Georgescu, C, Gevers, E, Gilkes, C, Glynn, N, Goldman, JE, Goldstone, AP, Góth, M, Green, A, Greenhalgh, L, Grieve, J, Griz, L, Guitelman, M, Gürlek, A, Gurnell, M, Hamblin, PS, Hana, V, Harding, P, Hay, E, Hilton, DA, Ho, W, Hong, G, Horváth, K, Howell, S, Howlett, TA, Höybye, C, Hunter, S, Idampitiya, C, Igaz, P, Imran, A, Inder, WJ, Iwata, T, Izatt, L, Jagadeesh, S, Johnston, C, Jose, B, Kaltsas, G, Kaplan, F, Karavitaki, N, Kastelan, D, Katz, M, Kearney, T, Kershaw, M, Khoo, B, Kiraly-Borri, C, Knispelis, R, Kovács, GL, Kumar, A, Kumar, AV, Kun, IZ, Kyriaku, A, Lambrescu, I, Lampe, AK, Laws, ER, Lebek-Szatanska, A, Lechan, RM, Leese, G, Levy, A, Levy, MJ, Lewandowski, K, Lin, E, Lo, J, Lyons, C, Maartens, N, Maghnie, M, Makaya, T, Marcus, H, Niedziela, M, Martin, N, Matsuno, A, McGowan, B, McQuaid, SE, Medic-Stojanoska, M, Mendoza, N, Mercado-Atri, M, Mettananda, S, Mezősi, E, Miljic, D, Miller, KK, Modenesi, S, Molitch, ME, Monson, J, Morris, DG, Morrison, PJ, Mosterman, B, Munir, A, Murray, RD, Musat, M, Musolino, N, Nachtigall, L, Nagi, D, Nair, R, Nelson, R, Newell-Price, J, Nikookam, K, Ogilivie, A, Orme, SM, O´Weickert, M, Pal, A, Pascanu, I, Patócs, A, Patterson, C, Pearce, SH, Giraldi, FP, Penney, L, Perez-Rivas, LG, Pfeifer, M, Pirie, F, Poplawski, N, Popovic, V, Powell, M, Pullan, P, Quinton, R, Radian, S, Randeva, H, Reddy, N, Rees, A, Renals, V, de Oliveira, AR, Richardson, T, Rodd, C, Ross, RJM, Roncaroli, F, Ryan, F, Salvatori, R, Schöfl, C, Shears, D, Shotliff, K, Skelly, R, Snape, K, Soares, BS, Somasundaram, N, Spada, A, Sperber, J, Spoudeas, H, Stelmachowska-Banas, M, Stewart, S, Storr, HL, Strasburger, C, Street, ME, Suter-Widmer, I, Suthers, G, Swords, F, Syro, LV, Swantje, B, Sze, C, Taylor, J, Thakker, RV, Tham, E, Thompson, C, Thorner, MO, Tóth, M, Trainer, PJ, Tsagarakis, S, Twine, G, Tzanela, M, Vadasz, J, Vaidya, B, Vaks, V, Vance, ML, Verkauskiene, R, Von Esch, H, Wass, JA, Waterhouse, M, Webb, S, Weber, A, Wernig, F, Widell, H, Yamada, S, Yap, P, Yarman, S, Yeoh, P, Yoshimoto, K, Yuen, K, and Zammitt, NN
- Abstract
Context\ud \ud Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene are responsible for a subset of familial isolated pituitary adenoma (FIPA) cases and sporadic pituitary neuroendocrine tumors (PitNETs).\ud \ud \ud \ud Objective\ud \ud To compare prospectively diagnosed AIP mutation-positive (AIPmut) PitNET patients with clinically presenting patients and to compare the clinical characteristics of AIPmut and AIPneg PitNET patients.\ud \ud \ud \ud Design\ud \ud 12-year prospective, observational study.\ud \ud \ud \ud Participants & Setting\ud \ud We studied probands and family members of FIPA kindreds and sporadic patients with disease onset ≤18 years or macroadenomas with onset ≤30 years (n = 1477). This was a collaborative study conducted at referral centers for pituitary diseases.\ud \ud \ud \ud Interventions & Outcome\ud \ud AIP testing and clinical screening for pituitary disease. Comparison of characteristics of prospectively diagnosed (n = 22) vs clinically presenting AIPmut PitNET patients (n = 145), and AIPmut (n = 167) vs AIPneg PitNET patients (n = 1310).\ud \ud \ud \ud Results\ud \ud Prospectively diagnosed AIPmut PitNET patients had smaller lesions with less suprasellar extension or cavernous sinus invasion and required fewer treatments with fewer operations and no radiotherapy compared with clinically presenting cases; there were fewer cases with active disease and hypopituitarism at last follow-up. When comparing AIPmut and AIPneg cases, AIPmut patients were more often males, younger, more often had GH excess, pituitary apoplexy, suprasellar extension, and more patients required multimodal therapy, including radiotherapy. AIPmut patients (n = 136) with GH excess were taller than AIPneg counterparts (n = 650).\ud \ud \ud \ud Conclusions\ud \ud Prospectively diagnosed AIPmut patients show better outcomes than clinically presenting cases, demonstrating the benefits of genetic and clinical screening. AIP-related pituitary disease has a wide spectrum ranging from aggressively growing lesions to stable or indolent disease course.
- Published
- 2020
6. High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry
- Author
-
Valassi, E, Tabarin, A, Brue, T, Feelders, RA, Reincke, M, Netea-Maier, R, Toth, M, Zacharieva, S, Webb, SM, Tsagarakis, S, Chanson, P, Pfeiffer, M, Droste, M, Komerdus, I, Kastelan, D, Maiter, D, Chabre, O, Franz, H, Santos, A, Strasburger, CJ, Trainer, PJ, Newell-Price, J, Ragnarsson, O, Ambroglo, A, Aranda, G, Arosio, M, Balomenaki, M, Beck-Peccoz, P, Berr-Kirmair, C, Bolanowski, M, Bollerslev, J, Thierry, B, Carvalho, D, Cavagnini, F, Christ, E, Demtroder, F, Denes, J, Dimopoulou, C, Dreval, A, Dusek, T, Erdinc, E, Evang, JA, Fazel, J, Fica, S, Ghigo, E, Greenman, Y, Greisa, V, Halperin, I, Hanzu, FA, Hermus, A, Johannsson, G, Kamenicky, P, Kasperlik-Zaluska, A, Kirchner, J, Darko, K, Kraljevic, I, Kruszynska, A, Lambrescu, I, Lang, S, Luger, A, Marpole, N, Martin, S, Martinie, M, Moros, O, Orbetzova, M, Paiva, I, Giraldi, FP, Pereira, AM, Pickel, J, Pirags, V, Reghina, AD, Riesgo, P, Roberts, M, Roerink, S, Roig, O, Rowan, C, Rudenko, P, Sahnoun, MA, Salvador, J, Sigurjonsdottir, HA, Polovina, TS, Smith, R, Stachowska, B, Stalla, G, Toke, J, Ubina, E, Vinay, S, Wagenmakers, M, Werner, S, Young, J, Zdunowski, P, Zopf, K, Zopp, S, Zosin, I, and ERCUSYN Study Grp
- Abstract
Objective: Patients with Cushing's syndrome (CS) have increased mortality. The aim of this study was to evaluate the causes and time of death in a large cohort of patients with CS and to establish factors associated with increased mortality. Methods: In this cohort study, we analyzed 1564 patients included in the European Registry on CS (ERCUSYN); 1045 (67%) had pituitary-dependent CS, 385 (25%) adrenal-dependent CS, 89 (5%) had an ectopic source and 45 (3%) other causes. The median (IQR) overall follow-up time in ERCUSYN was 2.7 (1.2-5.5) years. Results: Forty-nine patients had died at the time of the analysis; 23 (47%) with pituitary-dependent CS, 6 (12%) with adrenal-dependent CS, 18 (37%) with ectopic CS and two (4%) with CS due to other causes. Of 42 patients whose cause of death was known, 15 (36%) died due to progression of the underlying disease, 13 (31%) due to infections, 7 (17%) due to cardiovascular or cerebrovascular disease and 2 due to pulmonary embolism. The commonest cause of death in patients with pituitary-dependent CS and adrenal-dependent CS were infectious diseases (n = 8) and progression of the underlying tumor (n = 10) in patients with ectopic CS. Patients who had died were older and more often males, and had more frequently muscle weakness, diabetes mellitus and ectopic CS, compared to survivors. Of 49 deceased patients, 22 (45%) died within 90 days from start of treatment and 5 (10%) before any treatment was given. The commonest cause of deaths in these 27 patients were infections (n = 10; 37%). In a regression analysis, age, ectopic CS and active disease were independently associated with overall death before and within 90 days from the start of treatment. Conclusion: Mortality rate was highest in patients with ectopic CS. Infectious diseases the commonest cause of death soon after diagnosis, emphasizing the need for careful vigilance at that time, especially in patients presenting with concomitant diabetes mellitus.
- Published
- 2019
7. Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN
- Author
-
Valassi, Elena, Feelders, Richard, Maiter, Dominique, Chanson, Philippe, Yaneva, Maria, Reincke, Martin, Krsek, Michal, Tóth, Miklós, Webb, Susan M., Santos, Alicia, Paiva, Isabel, Komerdus, Irina, Droste, Michael, Tabarin, Antoine, Strasburger, Christian J, Franz, Holger, Trainer, Peter J, Newell-Price, John, Wass, John A H, Papakokkinou, Eleni, Ragnarsson, Oskar, Ambrogio, A., Aranda, G., Arosio, M., Balomenaki, M., Beck-Peccoz, P., Berr-Kirmair, C., Bolanowski, M., Bollerslev, J., Thierry, B., Carvalho, D., Cavagnini, F., Christ, E., Demtröder, F., Denes, J., Dimopoulou, C., Dreval, A., Dusek, T., Erdinc, E., Evang, J. A., Fazel, J., Fica, S., Ghigo, E., Goth, M., Greenman, Y., Greisa, V., Halperin, I., Hanzu, F. A., Hermus, A., Johannsson, G., Kamenicky, P., Kasperlik-Zaluska, A., Kirchner, J., Darko, K., Kraljevic, I., Kruszynska, A., Lambrescu, I., Lang, S., Luger, A., Marpole, N., Martin, S., Martinie, M., Moros, O., Orbetzova, M., Pecori Giraldi, F., Pereira, A. M., Pickel, J., Pirags, V., Reghina, A. D., Roberts, M., Roerink, S., Roig, O., Rowan, C., Rudenko, P., Sahnoun, M. A., Salvador, J., Sigurjonsdottir, H. A., Skoric Polovina, T., Smith, R., Stachowska, B., Stalla, G., Tőke, J., Ubina, E., Vinay, S., Wagenmakers, M., Werner, S., Young, J., Zdunowski, P., Zopf, K., Zopp, S., Zosin, I., Internal Medicine, and UCL - (SLuc) Service d'endocrinologie et de nutrition
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,Cushing's syndrome ,ERCUSYN ,health-related quality of life ,Endocrinology, Diabetes and Metabolism ,Endocrinology ,Hydrocortisone ,Long term follow up ,030209 endocrinology & metabolism ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,Surveys and Questionnaires ,medicine ,Humans ,In patient ,Prospective Studies ,Pituitary ACTH Hypersecretion ,Glucocorticoids ,Depression (differential diagnoses) ,Health related quality of life ,business.industry ,Cushing's disease ,Middle Aged ,medicine.disease ,Diabetes and Metabolism ,030220 oncology & carcinogenesis ,Etiology ,Quality of Life ,Female ,business - Abstract
Objective: Hypercortisolism in Cushing's syndrome (CS) is associated with impaired health-related quality of life (HRQoL), which may persist despite remission. We used the data entered into the European Registry on Cushing's syndrome (ERCUSYN) to evaluate if patients with CS of pituitary origin (PIT-CS) have worse HRQoL, both before and after treatment than patients with adrenal causes (ADR-CS). Methods: Data from 595 patients (492 women; 83%) who completed the CushingQoL and/or EQ-5D questionnaires at baseline and/or following treatment were analysed. Results: At baseline, HRQoL did not differ between PIT-CS (n = 293) and ADR-CS (n = 120) on both EuroQoL and CushingQoL. Total CushingQoL score in PIT-CS and ADR-CS was 41 ± 18 and 44 ± 20, respectively (P = .7). At long-time follow-up (>1 year after treatment) total CushingQoL score was however lower in PIT-CS than ADR-CS (56 ± 20 vs 62 ± 23; P = .045). In a regression analysis, after adjustment for baseline age, gender, remission status, duration of active CS, glucocorticoid dependency and follow-up time, no association was observed between aetiology and HRQoL. Remission was associated with better total CushingQoL score (P < .001), and older age at diagnosis with worse total score (P = .01). Depression at diagnosis was associated with worse total CushingQoL score at the last follow-up (P < .001). Conclusion: PIT-CS patients had poorer HRQoL than ADR-CS at long-term follow-up, despite similar baseline scoring. After adjusting for remission status, no interaetiology differences in HRQoL scoring were found. Age and presence of depression at diagnosis of CS may be potential predictors of worse HRQoL regardless of CS aetiology.
- Published
- 2018
8. Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN
- Author
-
Valassi, Elena, primary, Franz, Holger, additional, Brue, Thierry, additional, Feelders, Richard A, additional, Netea-Maier, Romana, additional, Tsagarakis, Stylianos, additional, Webb, Susan M, additional, Yaneva, Maria, additional, Reincke, Martin, additional, Droste, Michael, additional, Komerdus, Irina, additional, Maiter, Dominique, additional, Kastelan, Darko, additional, Chanson, Philippe, additional, Pfeifer, Marija, additional, Strasburger, Christian J, additional, Tóth, Miklós, additional, Chabre, Olivier, additional, Krsek, Michal, additional, Fajardo, Carmen, additional, Bolanowski, Marek, additional, Santos, Alicia, additional, Trainer, Peter J, additional, Wass, John A H, additional, Tabarin, Antoine, additional, _, _, additional, Ambrogio, A, additional, Aranda, G, additional, Arosio, M, additional, Balomenaki, M, additional, Beck-Peccoz, P, additional, Berr-Kirmair, C, additional, Bollerslev, J, additional, Carvalho, D, additional, Cavagnini, F, additional, Christ, E, additional, Demtröder, F, additional, Denes, J, additional, Dimopoulou, C, additional, Dreval, A, additional, Dusek, T, additional, Erdinc, E, additional, Evang, J A, additional, Fazel, J, additional, Fica, S, additional, Ghigo, E, additional, Goth, M, additional, Greenman, Y, additional, Greisa, V, additional, Halperin, I, additional, Hanzu, FA, additional, Hermus, A, additional, Johannsson, G, additional, Kamenicky, P, additional, Kasperlik-Zaluska, A, additional, Kirchner, J, additional, Kraljevic, I, additional, Kruszynska, A, additional, Lambrescu, I, additional, Lang, S, additional, Luger, A, additional, Marpole, N, additional, Martin, S, additional, Martinie, M, additional, Moros, O, additional, Newell-Price, J, additional, Orbetzova, M, additional, Paiva, I, additional, Pecori Giraldi, F, additional, Pereira, A M, additional, Pickel, J, additional, Pirags, V, additional, Ragnarsson, O, additional, Reghina, A D, additional, Riesgo, P, additional, Roberts, M, additional, Roerink, S, additional, Roig, O, additional, Rowan, C, additional, Rudenko, P, additional, A Sahnoun, M, additional, Salvador, J, additional, Sigurjonsdottir, HA, additional, Skoric Polovina, T, additional, Smith, R, additional, Stachowska, B, additional, Stalla, G, additional, Tőke, J, additional, Ubina, E, additional, Vinay, S, additional, Wagenmakers, M, additional, Werner, S, additional, Young, J, additional, Zdunowski, P, additional, Zopf, K, additional, Zopp, S, additional, and Zosin, I, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Aggressive multifocal angiomyxoma - a surgical challenge
- Author
-
Lambrescu, I, primary, Blaga, C, additional, Stefan, C, additional, Soare, I, additional, and Fica, S, additional
- Published
- 2016
- Full Text
- View/download PDF
10. Iatrogenic Cushing's syndrome related to the interaction between oral budesonide with fluvoxamine: a case report
- Author
-
Martin, C. S., primary, Blaga, C., additional, Lambrescu, I. M., additional, Fierbințeanu-Braticevici, C., additional, and Fica, S., additional
- Published
- 2015
- Full Text
- View/download PDF
11. Well logging digitization
- Author
-
Malureanu, I., Lambrescu, I., and Stoica, D.
- Published
- 2005
12. Computer aided modeling of the quadrilateral mechanism
- Author
-
Lambrescu, I. and Popa, A.
- Published
- 2004
13. Some aspects regarding the stress distribution in the vessel element – asymmetric conic reduction. Part I – building the model
- Author
-
Lambrescu, I., Pupazescu, A., and Popa, A.
- Published
- 2004
14. Bacterial products initiation of alpha-synuclein pathology: an in vitro study.
- Author
-
Ioghen OC, Gaina G, Lambrescu I, Manole E, Pop S, Niculescu TM, Mosoia O, Ceafalan LC, and Popescu BO
- Subjects
- Humans, Parkinson Disease metabolism, Parkinson Disease pathology, Cell Line, Tumor, Glycolipids metabolism, Dopaminergic Neurons metabolism, Dopaminergic Neurons pathology, Dopaminergic Neurons drug effects, Cell Survival drug effects, alpha-Synuclein metabolism, Lipopolysaccharides
- Abstract
Parkinson's Disease (PD) is a prevalent and escalating neurodegenerative disorder with significant societal implications. Despite being considered a proteinopathy, in which the aggregation of α-synuclein is the main pathological change, the intricacies of PD initiation remain elusive. Recent evidence suggests a potential link between gut microbiota and PD initiation, emphasizing the need to explore the effects of microbiota-derived molecules on neuronal cells. In this study, we exposed dopaminergic-differentiated SH-SY5Y cells to microbial molecules such as lipopolysaccharide (LPS), rhamnolipid, curli CsgA and phenol soluble modulin α-1 (PSMα1). We assessed cellular viability, cytotoxicity, growth curves and α-synuclein levels by performing MTS, LDH, real-time impedance readings, qRT-PCR and Western Blot assays respectively. Statistical analysis revealed that rhamnolipid exhibited concentration-dependent effects, reducing viability and inducing cytotoxicity at higher concentrations, increasing α-synuclein mRNA and protein levels with negative effects on cell morphology and adhesion. Furthermore, LPS exposure also increased α-synuclein levels. Curli CsgA and PSMα-1 showed minimal or no changes. Our findings suggest that microbiota-derived molecules, particularly rhamnolipid and LPS, impact dopaminergic neurons by increasing α-synuclein levels. This study highlights the potential involvement of gut microbiota in initiating the upregulation of α-synuclein that may further initiate PD, indicating the complex interplay between microbiota and neuronal cells., Competing Interests: Declarations. Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. Experimental and Numerical Investigations of Cement Bonding Properties at Elevated Temperatures-The Effect of Sample Cooling.
- Author
-
Lambrescu I and Teodoriu C
- Abstract
Well integrity is currently defined through the concept of well barriers, in which one or more barriers are used to prevent unwanted fluid flow. Many papers have highlighted that the casing-cement interfacial bonding is critical for well integrity, but many discrepancies between laboratory experiments and field data have been noticed. The use of finite element analysis is now established as an alternative to complex in situ tests, but these simulations are sensitive to the input parameters, which results in many discrepancies across published works. Currently, the cohesive zone material (CZM) method is considered to offer good results if the correct parameters are selected or experimentally determined. The novelty of this paper lies in the development of a better workflow that enables the simulation of three processes that are acting on the laboratory-scale casing-cement system: temperature changes, debonding, and post-debonding behavior. The aim of this paper is to fully understand the debonding process within laboratory-scale samples, and thus to eventually enable upscaling in the near future. The paper presents a new workflow generated using FEM that allows us to determine the contact stresses at the casing-cement interface during temperature changes at the moment of debonding and post-debonding. The results presented within this paper show that temperature samples tested according to the push-down setup will provide similar interfacial bonding shear strength values; however, post-debonding, there is a remaining frictional force slightly higher than that of the room-temperature samples. In this case, the results are within a 5% error of the average field data, which is slightly higher than in our previous experiments, where only room temperature data were considered. A major outcome of our paper is the demonstration of the existence of friction forces after debonding, which are a result of radial stresses induced during the debonding process.
- Published
- 2022
- Full Text
- View/download PDF
16. Application of Droplet Digital PCR Technology in Muscular Dystrophies Research.
- Author
-
Lambrescu I, Popa A, Manole E, Ceafalan LC, and Gaina G
- Subjects
- Female, Humans, Polymerase Chain Reaction methods, Pregnancy, Quality of Life, Technology, Muscular Dystrophies diagnosis, Muscular Dystrophies genetics, Muscular Dystrophies therapy, Muscular Dystrophy, Duchenne diagnosis, Muscular Dystrophy, Duchenne genetics
- Abstract
Although they are considered rare disorders, muscular dystrophies have a strong impact on people's health. Increased disease severity with age, frequently accompanied by the loss of ability to walk in some people, and the lack of treatment, have directed the researchers towards the development of more effective therapeutic strategies aimed to improve the quality of life and life expectancy, slow down the progression, and delay the onset or convert a severe phenotype into a milder one. Improved understanding of the complex pathology of these diseases together with the tremendous advances in molecular biology technologies has led to personalized therapeutic procedures. Different approaches that are currently under extensive investigation require more efficient, sensitive, and less invasive methods. Due to its remarkable analytical sensitivity, droplet digital PCR has become a promising tool for accurate measurement of biomarkers that monitor disease progression and quantification of various therapeutic efficiency and can be considered a tool for non-invasive prenatal diagnosis and newborn screening. Here, we summarize the recent applications of droplet digital PCR in muscular dystrophy research and discuss the factors that should be considered to get the best performance with this technology.
- Published
- 2022
- Full Text
- View/download PDF
17. Experimental and Numerical Investigations of Cement Bonding Properties.
- Author
-
Lambrescu I, Teodoriu C, and Amani M
- Abstract
Well integrity is of high importance during the entire well life span especially when renewable energy resources such as geothermal are designed to cover the increasing world energy demand. Many studies have documented the importance of the casing-cement interfacial bonding to ensure critical well integrity achievements; however, laboratory experiments and field data are not always aligned. Furthermore, Finite Element Analysis shows relatively high discrepancies compared with the results of various scholarly published works. The limitations in the FEA are most probably generated by the casing-cement interaction modeling parameters. Typically, the contact between casing and cement is modeled using the so-called CZM method, which includes the shear debonding process into the FEA. Several setups have been used in the past to determine the interfacial casing-cement bonding shear strength. Some of these setups are briefly summarized herein. The novelty of this paper consists in the combination of a relatively simple experimental setup with the finite element modeling of the experiment itself to demonstrate that it is important to acquire accurate laboratory data for debonding simulations and, thus, to improve the well integrity prediction. The aim of this paper is to better understand the limitations of the finite element method when modeling shear bonding of the cement and, in the same, to verify that the proposed experimental setup can be modelled using numerical approaches. The successful numerical simulation can later be used for upscaled models. The results confirm the experimental push down setup and aid engineers to further understand and validate CZM models and optimize the well design to achieve maximum well integrity potential. Our results are within 1% error from the average field data.
- Published
- 2021
- Full Text
- View/download PDF
18. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
- Author
-
Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, and Fazio N
- Subjects
- Humans, Molecular Targeted Therapy methods, Sunitinib, Antineoplastic Agents therapeutic use, Everolimus therapeutic use, Indoles therapeutic use, Neuroendocrine Tumors drug therapy, Pancreatic Neoplasms drug therapy, Pyrroles therapeutic use
- Abstract
Neuroendocrine tumors (NETs) represent a large and heterogeneous group of malignancies with various biological and clinical characteristics, depending on the site of origin and the grade of tumor proliferation. In NETs, as in other cancer types, molecularly targeted therapies have radically changed the therapeutic landscape. Recently two targeted agents, the mammalian target of rapamycin inhibitor everolimus and the tyrosine kinase inhibitor sunitinib, have both demonstrated significantly prolonged progression free survival in patients with advanced pancreatic NETs. Despite these important therapeutic developments, there are still significant limitations to the use of these agents due to the lack of accurate biomarkers for predicting tumor response and efficacy of therapy. In this review, we provide an overview of the current clinical data for the evaluation of predictive factors of response to/efficacy of everolimus and sunitinib in advanced pancreatic NETs. Surrogate indicators discussed include circulating and tissue markers, as well as non-invasive imaging techniques.
- Published
- 2017
- Full Text
- View/download PDF
19. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
- Author
-
Lambrescu I, Fica S, Martins D, Spada F, Cella C, Bertani E, Rubino M, Gibelli B, Grana C, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, and Fazio N
- Subjects
- Antineoplastic Agents pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Humans, Interferons administration & dosage, Neuroendocrine Tumors radiotherapy, Administration, Metronomic, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Neuroendocrine Tumors drug therapy
- Abstract
Metronomic therapy is characterized by the administration of regular low doses of certain drugs with very low toxicity. There have been numerous debates over the empirical approach of this regimen, but fewest side effects are always something to consider in order to improve patients' quality of life. Neuroendocrine tumors (NETs) are rare malignancies relatively slow-growing; therefore their treatment is often chronic, involving several different therapies for tumor growth control. Knowing that these tumors are highly vascularized, the anti-angiogenic aspect is highly regarded as something to be targeted in all patients harboring NETs. Additionally the metronomic schedule has proved to be effective on an immunological level, rendering this approach as a multi-targeted therapy. Rationalizing that advanced NETs are in many cases a chronic disease, with which patients can live for as long as possible, a systemic therapy with regular low doses and a very low toxicity is in many cases a judicious manner of pursuing stabilization. Metronomic schedule is usually correlated with chemotherapy in oncology, but other therapies, such as radiotherapy and biotherapy can be delivered in a metronomic like manner. This review describes clinical trials and case series involving metronomic therapies alone or in combination in patients with advanced NETs. Nowadays level of evidence about metronomic therapy in NETs is quite low, therefore future prospective clinical studies are needed to validate the metronomic approach in specific clinical settings., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.